Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 3 3Phase 1/2 3

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasms 2Advanced Cancer 2Malignancies Multiple 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × linrodostat × Clear all
NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed
20 enrolled

Advanced Cancer

NCT03192943 2019-04-01

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Bristol-Myers Squibb

Phase 1 Completed
11 enrolled

Advanced Cancer

NCT03346837 2018-02-28

A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects

Bristol-Myers Squibb

Phase 1 Completed
53 enrolled

Malignancies Multiple

NCT03312426 2018-01-19

An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants

Bristol-Myers Squibb

Phase 1 Completed
32 enrolled
Tumor-Agnostic

Neoplasms

NCT03247283 2017-11-06

Pharmacokinetics and Metabolism Study in Healthy Male Participants

Bristol-Myers Squibb

Phase 1 Completed
9 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡